Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.
Faron is a Turku, Finland-based clinical-stage biopharmaceutical company.
Inside Information: Faron Announces First HMA-Failed MDS Patient Dosed With Bexmarilimab As Part Of Phase 2 Of BEXMAB Trial menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) is appointing Dr Birge Berns as its interim chief medical officer (CMO), replacing Dr Marie-Louise.
Faron Appoints Dr Birge Berns, MD as Interim Chief Medical Officer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Faron Pharmaceuticals Ltd - Turku, Finland-based.